Fundz Deep Dive

Everything you need to win CureVac — in one platform.

Who to reach, what to say, and why now on CureVac — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on CureVac — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply

Grounded in signals no one else has — tuned to their persona.

Signals no one else has

UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.

Verified contact + click-to-call

The decision-maker’s email and mobile — dial in-browser.

Cure Vac N.V. Appoints Thaminda Ramanayake As Chief Business Officer

RECENTLY ACQUIREDApr 29, 2024•about 2 years ago

Company

CureVac

TübingenBiotechnologyHealth Care

Description

CureVac N.V., a global biopharmaceutical company, has announced the appointment of Thaminda Ramanayake to the role of Chief Business Officer, effective June 1, 2024. Mr. Ramanayake brings over fifteen years of experience in biopharma company development and deal-making, with a strong track record of successful clinical collaborations, M&A, asset in-licensing, and strategic financing initiatives across multiple therapeutic areas.

Company Information

Company

CureVac

Location

Tübingen, Baden-Württemberg, Germany

About

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for CureVac's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months